P2RX4 and breast cancer: rs28360472 was shown to lead to loss of function of P2RX4 by disrupting the agonist binding site40, which suggests that this change in P2RX4 function plays a role in increasing susceptibility to breast cancer and of MS susceptibility, while reducing susceptibility to colon cancer.